Dr Reddy’s re-launches Zenatane in US market

Our Bureau Hyderabad | Updated on June 04, 2019 Published on June 04, 2019

Dr Reddy’s Laboratories has announced the re-launch of Zenatane (Isotretinoin Capsules)

Pharma major Dr Reddy’s Laboratories has announced the re-launch of Zenatane (Isotretinoin Capsules), a therapeutic equivalent generic version of Accutane, approved by the US Food and Drug Administration (USFDA).

The product is being launched with an approved Risk Evaluation and Mitigation Strategy (REMS) Programme.

“We’re pleased to bring this product back to market for the customers and patients who will benefit from access to this medicine, and who have had witnessed limited supply and options in the market place,” Marc Kikuchi, Chief Executive Officer, North America Generics, said.

“Furthermore, this is important for our company as we have commercialised the first Softgel dosage product from Dr Reddy’s own manufacturing plant to ensure consistent and robust supply for this product in the US market,” he said.

The Zenatane brand and generic had sales of approximately $525 million in the US for the most twelve months ending in March 2019, according to IQVIA Health.

Published on June 04, 2019

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!


Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.